Aging, Insulin Resistance, and Dilated Cardiomyopathy

衰老、胰岛素抵抗和扩张型心肌病

• 批准号: 7190036
• 负责人: Richard P Shannon
• 金额: $ 33.6万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-01-15 至 2008-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7190036
• 关键词: 2,4-thiazolidinedione; Accounting; Acids; Acute; Adipose tissue; Admission activity; Affect; Age; Aging; American; Amides; Appendix; Attenuated; Body fat; Body mass index; Canis familiaris; Cardiac; Cardiomyopathies; Cardiovascular system; Clinical; Condition; Congestive Heart Failure; Conscious; Continuous Infusion; Coronary; Data; Dependence; Development; Dilated Cardiomyopathy; Distal; Elderly; Esterified Fatty Acids; Euglycemic Clamping; Evolution; Excess Mortality; Family; Fatty acid glycerol esters; Functional disorder; Generations; Glucose; Glucose Clamp; Heart; Heart failure; Hospitals; Hour; Incidence; Infusion procedures; Injury; Insulin; Insulin Resistance; Laboratories; Life; Mediating; Metabolic; Modeling; Molecular; Morbidity - disease rate; Myocardial; Myocardium; Nature; Non-Insulin-Dependent Diabetes Mellitus; Nuclear Receptors; Obesity; Outcome; PTEN gene; Pathogenesis; Performance; Peroxisome Proliferator-Activated Receptors; Pharmacological Treatment; Phosphoric Monoester Hydrolases; Phosphorylation; Physiological; Play; Predisposition; Property; Residual state; Risk; Role; Series; Serine; Severities; Signal Transduction; Site; Skeletal Muscle; Societies; Staging; Standards of Weights and Measures; Testing; Therapeutic; Thiazolidinediones; Thinking; Time; Tumor Suppressor Proteins; Ventricular Dysfunction; Visceral; age effect; age related; aged; base; cardiovascular risk factor; cohort; demographics; deprivation; design; fatty acid transport; glucagon-like peptide 1; glucose uptake; hemodynamics; improved; injured; inorganic phosphate; instrument; insulin sensitivity; insulin signaling; integrin-linked kinase; member; mortality; oxidation; preference; prevent; proglucagon; programs; receptor; recombinant peptide; response; senescence; uptake

Congestive heart failure is a leading cause of morbidity and mortality in the elderly, although the mechanisms to explain the enhanced proclivity are poorly understood. It remains debatable as to whether the age-associated propensity to cardiovascular dysfunction is attributable to aging per se or the accumulation of cardiovascular risk factors that accrue over time. In particular, aging has been closely associated with the development of increased visceral adiposity that has been implicated in the pathogenesis of age associated insulin resistance. Whether age associated insulin resistance contributes to the progression of cardiac dysfunction following myocardial injury has not been explored systematically. The altered cellular actions of insulin that underlie physiological insulin resistance may have significant consequences to the failing heart. The injured myocardium develops an evolving dependence on glucose as its preferred metabolic substrate. The preference is dependent upon the efficiencies of oxidation of glucose in the generation of high-energy phosphates. This preference becomes a requirement as the ability to oxidized fat acids is limited through a series of molecular switches in key regulatory components of fatty acid transport and oxidation. We have determined that advanced, decompensated stages of dilated cardiomyopathy are associated with the development of myocardial insulin resistance, which limits myocardial glucose uptake and oxidation. These physiological features are associated with cellular insulin signaling abnormalities in the myocardium that are distinct from those observed in skeletal muscle and adipose tissue in other insulin resistant states. Together, aging and heart failure share the common pathophysiological features of insulin resistance. Whether the effects are additive or synergistic in explaining the increased incidence and severity of heart failure in the elderly remains to be determined. We will determine if aging is associated with accelerated progression of heart failure in conscious dogs with pacing induced dilated cardiomyopathy. We will define the physiological and cellular effects of insulin resistance in the senescent myocardium during the evolution of dilated cardiomyopathy. Finally, we will determine if overcoming myocardial insulin resistance in the aging and failing heart will prevent the progression of dilated cardiomyopathy.

充血性心力衰竭是老年人发病率和死亡率的主要原因， 解释增强倾向的机制知之甚少。关于是否 与年龄相关的心血管功能障碍倾向可归因于衰老本身或 随着时间的推移，心血管风险因素的积累。特别是，老龄化已经密切 与内脏肥胖增加的发展有关， 与年龄相关的胰岛素抵抗的发病机制。年龄相关的胰岛素抵抗是否有助于 心肌损伤后心功能不全的进展尚未系统地研究。 生理性胰岛素抵抗的基础胰岛素细胞作用的改变可能具有显著的 心脏衰竭的后果受损的心肌对葡萄糖的依赖性不断发展， 其优选的代谢底物。该偏好取决于葡萄糖氧化的效率 产生高能磷酸盐的过程这种偏好成为一种要求， 氧化的脂肪酸通过脂肪酸关键调节组分中的一系列分子开关来限制 运输和氧化。我们已经确定晚期失代偿期的扩张性心脏病 心肌病与心肌胰岛素抵抗的发展有关， 心肌葡萄糖摄取和氧化。这些生理特征与细胞胰岛素有关 心肌中的信号传导异常与骨骼肌中观察到的信号传导异常不同， 其他胰岛素抵抗状态下的脂肪组织。 总之，衰老和心力衰竭具有胰岛素抵抗的共同病理生理学特征。 在解释心脏病的发生率和严重程度增加时， 老年人的失败仍有待确定。我们将确定老化是否与加速 起搏诱导扩张型心肌病的清醒犬心力衰竭的进展。我们将定义 胰岛素抵抗在衰老心肌演变过程中的生理和细胞效应 扩张型心肌病最后，我们将确定是否克服心肌胰岛素抵抗在老化 心脏衰竭可以阻止扩张型心肌病的发展